Construction of a Database for TTP

NCT05571774 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Soochow University

Phase

Observational

Started

2022-10-20

Last updated

2022-10-07

Condition(s) studied

TTP - Thrombotic Thrombocytopenic Purpura

Investigational drug(s) / intervention(s)

collection data

collection data: collection data

Study summary

Information about patients was collected by reviewing the Hitech case system and telephone and outpatient follow-up, and the case database was constructed by Epidata software. The sample size is expected to be 200 cases, the participating hospital is the First Affiliated Hospital of Soochow University, and the study time frame is from Oct 20, 2022, to Oct 20, 2027. The observation indexes of the study include the basic information of patients' age and gender and the clinical related data of thrombotic thrombocytopenic purpura.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: \- Subjects diagnosed with severe ADAMTS13 deficiency, defined as ADAMTS13 activity \<10%, documented in the patient's medical history or at screening. Exclusion Criteria: \- The investigator considers the subject unable or unwilling to cooperate with the study procedures.

Primary outcome measure(s)

Number of participants with stroke — 5 years from the time of entering the database.
Stroke was assessed with MRI imaging.

Trial sites (1)

Facility	City	Region	Status
the first affiliated hospital of Soochow university	Suzhou	Jiangsu	Recruiting

More The First Affiliated Hospital of Soochow University trials in China

A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML Recruiting

Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML Starting soon

A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia Starting soon

N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy Active, not recruiting

CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05571774 on ClinicalTrials.gov ↗ ← All trials in China